Results 241 to 250 of about 179,831 (305)

Immunoprofiling, sex‐ and age‐related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma

British Journal of Haematology, EarlyView.
Multimodal integration of sex‐ and age‐related immune‐gene signatures with baseline tumor burden (TMTV1) improves prediction of treatment response in adolescents and young adults with classical Hodgkin lymphoma. Summary The study investigates how sex and age influence treatment response in paediatric, adolescent and young adult (AYA) classical Hodgkin ...
Valli De Re, Egesta Lopci, Giulia Brisotto, Caterina Elia, Angelo Vitullo, Veronica Paduano, Mariangela De Zorzi, Lara Mussolin, Paola Quarello, Simona Bianchi, Salvatore Buffardi, Alberto Garaventa, Paola Muggeo, Marta Pillon, Alessandra Sala, Luciana Vinti, Emanuele d'Amore, Christine Mauz‐Korholz, Maurizio Mascarin, on behalf of the AIEOP Hodgkin's Lymphoma Study Group, Alberto Garaventa, Alessandra Sala, Antonella Sau, Assunta Tornesello, Daniela Galimberti, Domenico Sperlì, Elena Facchini, Eulalia Galea, Federico Verzegnassi, Fiorina Giona, Francesca Rossi, Fulvio Porta, Irene D’Alba, Katia Perruccio, Luciana Vinti, Marco Zecca, Marta Pillon, Massimo Provenzi, Maurizio Bianchi, Maurizio Mascarin, Monica Cellini, Nadia Vacca, Paola Muggeo, Patrizia Bertolini, Piero Farruggia, Raffaella De Santis, Roberta Pericoli, Rosamaria Mura, Salvatore Buffardi, Salvatore D’Amico, Sayla Bernasconi, Simona Rinieri, Simone Cesaro, Tommaso Casini, Valerio Cecinati   +54 more
wiley   +1 more source

Glutamate metabotropic receptor 4 in breast cancer: a potential and specific target for chimeric antigen receptor therapy. [PDF]

Front Oncol
Xu Y, Hayierhan A, Chen Z, Ma Y, Zhang W, Xu C, Mei R, Zhou X, Zhu Y, Sun P, Wu J.   +10 more
europepmc   +1 more source

Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable

British Journal of Haematology, EarlyView.
Summary Clinical decision‐making based on myeloma‐defining event criteria using thresholds for involved serum free light chain level of 10 mg/dL and ratio of involved to uninvolved light chain of >100 is a poor indicator for the risk of progression to multiple myeloma.
Gurmukh Singh
wiley   +1 more source

Common gamma chain cytokines-driven optimization of chimeric antigen receptor T cells: Mechanistic insights and future directions. [PDF]

World J Clin Oncol
Zuo DB, Chen ZH, Jin YM, Sang M, Sun XD, Guo A, Li XY, Wu JX, Ji KK, Zhou H.   +9 more
europepmc   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

Efficacy of chimeric antigen receptor T-cell therapy in testicular relapse of pediatric acute lymphoblastic leukemia: a multicenter retrospective study. [PDF]

Front Immunol
Wang N, Tang Y, Zhuang Y, Cai J, Hu S, Yang X, Fang Y, Wu X, Wang N, Wang L, Zhai X, Yang M, Tian X, Wang Y, Li H, Zhao L, Li CK, Chen X, Zhu X.   +18 more
europepmc   +1 more source

Induction of IL‐9‐producing CD8+ T cells by ascochlorin derivatives

British Journal of Pharmacology, EarlyView.
A newly synthesised ascochlorin derivative, N184, induces small amounts of IL‐9‐producing CD8+ T cells. N184 improved the survival of CD8+ T cells and enhanced their antitumour activity, partially in an IL‐9‐dependent manner. The antitumour effect was completely dependent on IFNγ secretion rather than the cytotoxic activity of CD8+ T cells.
Natsumi Imano, Mikako Nishida, Miho Tokumasu, Weiyang Zhao, Nahoko Yamashita, Heiichiro Udono   +5 more
wiley   +1 more source

IL-21 promotes the anti-tumor effect of anti-CD47 chimeric antigen receptor macrophages in ovarian cancer. [PDF]

Commun Biol
Chen Y, Zhu X, Chen Y, Yang Z, Shen Z, Chen M, Liu C, Zhou Y, Wang H, Zhu M, Qiu J, Huang J, Han X, Wei W, Ruilin L, Hong W, Tu J.   +16 more
europepmc   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Chimeric antigen receptor macrophages: a new frontier in hepatocellular carcinoma treatment. [PDF]

Cancer Biol Med
Hei Leung RW, Ting Wong CT, Wah Lee TK.
europepmc   +1 more source